COMMUNIQUÉS West-GlobeNewswire

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
12/06/2019
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK, and Cambridge, MA, US, 12 [...]
Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company
12/06/2019
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its majority-owned subsidiary, [...]
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
12/06/2019
Key Highlights: Travelan ® shigellosis challenge studies in non-human primates successfully completed Travelan ® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan ® treated animals compared to [...]
Emerald Health Therapeutics Contracts for 1,200 Acres of Canadian Hemp Harvest, Reports Significant Progress on Factors Group Extraction Facility, and Forms US Hemp Subsidiary
12/06/2019
Emerald Aims to Harvest over 270,000 kg of Hemp in 2019, With the Potential to Produce Over 3,500 kg of Extracted CBD Oil VANCOUVER, British Columbia, June 12, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc [...]
Precision BioSciences Appoints Dario Scimeca as General Counsel
12/06/2019
DURHAM, N.C., June 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS ® genome editing platform [...]
Biohit Oyj B-shares Subscribed with Stock Options I 2013
12/06/2019
Biohit Oyj Stock Exchange Release June 12, 2019 at 13.15 a.m. (EEST) A total number of 88,552 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 12 February 2019 and 31 May 2019. These [...]
Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland
12/06/2019
Heidelberg, Germany, June 12, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today that two abstracts [...]
Philips announces exchange ratio for 2018 dividend in shares
12/06/2019
June 12, 2019 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend in shares for the year 2018 has been determined. The exchange ratio is 1 new [...]
TLC Presents New Pharmacokinetic and Toxicokinetic Data on TLC599 Following Intra-articular Injection in Dogs at EULAR 2019
12/06/2019
TLC599 showed locally sustained release profile up to 120 days, dose proportionality, minimal systemic exposure and potential for repeat dosing SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 12, 2019 (GLOBE [...]
Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
12/06/2019
Multicohort, multi-center, international Phase II study to evaluate the efficacy and safety of IPH4102 in patients with advanced T-cell lymphoma is ongoing Sézary syndrome cohort of the TELLOMAK study is designed to [...]
Présentation du design de l’essai « TELLOMAK» ainsi que des données précliniques d’IPH4102 dans le LTP à l’ICML 2019
12/06/2019
Cette étude de Phase II internationale, multicohorte et multicentrique, est en cours, évaluant l’efficacité et la tolérance d’IPH4102 chez des patients présentant un lymphome des cellules T avancé La cohorte syndrome de [...]
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
12/06/2019
Company to Host Investor Conference Call and Webcast of Mid-2019 Clinical Data Updates on Thursday, June 20 at 8:00 a.m. EDT CAMBRIDGE, Mass. and BEIJING, China, June 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: [...]
Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress
12/06/2019
Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24 th European Hematology Association (EHA) Congress Symposium will explore the landscape and potential [...]
Genfit: GENFIT Announces Active Participation in the 2nd Annual International NASH Day
12/06/2019
GENFIT Announces Active Participation in the 2nd Annual International NASH Day A year ago, GENFIT gathered an international coalition to support The NASH Education Program and launch the 1 st successful edition of [...]
GENFIT: GENFIT annonce sa participation active à la 2e Journée Internationale de la NASH
12/06/2019
GENFIT annonce sa participation active à la 2 e Journée Internationale de la NASH Il y a un an, GENFIT constituait une coalition internationale pour soutenir The NASH Education Program et lancer avec succès la 1 ere [...]
Eurobio Scientific and Vivo Medical Group enter into exclusive negotiations for the acquisition of two companies in the United Kingdom (addendum)
12/06/2019
Eurobio Scientific and Vivo Medical Group enter into exclusive negotiations for the acquisition of two companies in the United Kingdom (addendum) Paris, June 12, 2019 – 8:00 am Eurobio Scientific enters into exclusive [...]
Eurobio Scientific et Vivo Medical Group entrent en négociation exclusive pour l’acquisition de deux sociétés au Royaume-Uni (addendum)
12/06/2019
Eurobio Scientific et Vivo Medical Group entrent en négociation exclusive pour l’acquisition de deux sociétés au Royaume-Uni (addendum) Paris, le 12 juin 2019 – 8h00 Eurobio Scientific (FR0013240934, ALERS, éligible PEA [...]
Immunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST
12/06/2019
Press Release 12 June 2019 Immunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST Immunicum AB (publ) announced today the completion and positive topline results from its Phase [...]
Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
12/06/2019
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with active PsA achieved ACR50, and [...]

Pages